Google
ADCT — ADC THERAPEUTICS SA (Healthcare >> Biotechnology)
ADCT FAQ
What is ADCT's ROE?
ADC THERAPEUTICS SA reports a Return on Equity (ROE) of 63.31%.
What is ADCT's dividend yield?
ADC THERAPEUTICS SA offers a dividend yield of 0.00%.
What is ADCT's Deepscope Quality Score?
Deepscope rates ADCT's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ADCT?
Deepscope's AI Timing Score for ADCT is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ADCT belong to?
ADC THERAPEUTICS SA is classified under the Healthcare >> Biotechnology sector on the NYSE exchange.
|
USD 3.17
Price
-0.23
(-6.76%)
Day Change
|
|
|---|
ADCT, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 73 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.17 |
| PBV / Sector |
-2.00 / 4.53
|
| Earning Per Share | -1.00 |
| PE / Sector |
N/A / 16.80
|
| PEG or PE/Growth / Sector |
N/A / 0.51
|
| Average 1M Daily Value |
3.82 M
GREAT
|
| Average 1W Daily Value |
2.12 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-03 09:10:48 |
| Symbol | ADCT |
| Name | ADC THERAPEUTICS SA |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 127.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 432.45 / 8,614.17 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: BiopOle, Epalinges, Switzerland, 1066
Phone: 41 21 653 02 00
Website: https://www.adctherapeutics.com
Employees: 188
Sector: Healthcare >> Biotechnology
Description: ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
